Detail publikace

Catheter ablation versus antiarrhythmic drugs with risk factor modification for treatment of atrial fibrillation: a protocol of a randomised controlled trial (PRAGUE-25 trial)

OSMANCIK, P. HAVRANEK, S. BULKOVA, V. CHOVANCIK, j. ROUBICEK, T. HERMAN, D. CERNA, Z. TUKA, V. MATOULEK, M. FIALA, M. JIRAVSKY, O. STREGL-HRUSKOVA, S. LATINAK, A. KOTRYOVA, J. JARKOVSKY, J.

Originální název

Catheter ablation versus antiarrhythmic drugs with risk factor modification for treatment of atrial fibrillation: a protocol of a randomised controlled trial (PRAGUE-25 trial)

Typ

článek v časopise ve Web of Science, Jimp

Jazyk

angličtina

Originální abstrakt

Introduction Atrial fibrillation (AF), with a prevalence of 2%, is the most common cardiac arrhythmia. Catheter ablation (CA) has been documented to be superior to treatment by antiarrhythmic drugs (AADs) in terms of sinus rhythm maintenance. However, in obese patients, substantial weight loss was also associated with AF reduction. So far, no study has compared the modern non-invasive (AADs combined with risk factor modification (RFM)) approach with modern invasive (CA) treatment. The aim of the trial is to compare the efficacy of modern invasive (CA) and non-invasive (AADs with risk factor management) treatment of AF. Methods and analysis The trial will be a prospective, multicentre, randomised non-inferiority trial. Patients with symptomatic AF and a body mass index >30 will be enrolled and randomised to the CA or RFM arm (RFM+AAD) in a 1:1 ratio. In the CA arm, pulmonary vein isolation (in combination with additional lesion sets in non-paroxysmal patients) will be performed. For patients in the RFM+AAD arm, the aim will be a 10% weight loss over 6-12 months, increased physical fitness and a reduction in alcohol consumption. The primary endpoint will be an episode of AF or regular atrial tachycardia lasting >30s. The secondary endpoints include AF burden, clinical endpoints associated with AF reoccurrence, changes in the quality of life assessed using dedicated questionnaires, changes in cardiorespiratory fitness and metabolic endpoints. An AF freedom of 65% in the RFM+AAD and of 60% in the CA is expected; therefore, 202 patients will be enrolled to achieve the non-inferiority with 80% power, 5% one-sided alpha and a non-inferiority margin of 12%. Ethics and dissemination The PRAGUE-25 trial will determine if modern non-invasive AF treatment strategies are non-inferior to CA. The study was approved by the Ethics Committee of the University Hospital Kralovske Vinohrady. Results of the study will be disseminated on scientific conferences and in peer-reviewed scientific journals. After the end of follow-up, data will be available upon request to principal investigator.

Klíčová slova

Adult cardiology; NUTRITION & DIETETICS; Pacing & electrophysiology

Autoři

OSMANCIK, P.; HAVRANEK, S.; BULKOVA, V.; CHOVANCIK, j.; ROUBICEK, T.; HERMAN, D.; CERNA, Z.; TUKA, V.; MATOULEK, M.; FIALA, M.; JIRAVSKY, O.; STREGL-HRUSKOVA, S.; LATINAK, A.; KOTRYOVA, J.; JARKOVSKY, J.

Vydáno

15. 6. 2022

Nakladatel

BMJ PUBLISHING GROUP

Místo

LONDON

ISSN

2044-6055

Periodikum

BMJ Open

Ročník

12

Číslo

6

Stát

Spojené království Velké Británie a Severního Irska

Strany od

1

Strany do

8

Strany počet

8

URL

https://bmjopen.bmj.com/content/bmjopen/12/6/e056522.full.pdfb

BibTex

@article{BUT182413,
  author="OSMANCIK, P. and HAVRANEK, S. and BULKOVA, V. and CHOVANCIK, j. and ROUBICEK, T. and HERMAN, D. and CERNA, Z. and TUKA, V. and MATOULEK, M. and FIALA, M. and JIRAVSKY, O. and STREGL-HRUSKOVA, S. and LATINAK, A. and KOTRYOVA, J. and JARKOVSKY, J.",
  title="Catheter ablation versus antiarrhythmic drugs with risk factor modification for treatment of atrial fibrillation: a protocol of a randomised controlled trial (PRAGUE-25 trial)",
  journal="BMJ Open",
  year="2022",
  volume="12",
  number="6",
  pages="1--8",
  doi="10.1136/bmjopen-2021-056522",
  issn="2044-6055",
  url="https://bmjopen.bmj.com/content/bmjopen/12/6/e056522.full.pdfb"
}